[go: up one dir, main page]

DE69923559D1 - Methoden zur inhibierung von helicobacter pylori - Google Patents

Methoden zur inhibierung von helicobacter pylori

Info

Publication number
DE69923559D1
DE69923559D1 DE69923559T DE69923559T DE69923559D1 DE 69923559 D1 DE69923559 D1 DE 69923559D1 DE 69923559 T DE69923559 T DE 69923559T DE 69923559 T DE69923559 T DE 69923559T DE 69923559 D1 DE69923559 D1 DE 69923559D1
Authority
DE
Germany
Prior art keywords
methods
helicobacter pylori
inhibiting
inhibiting helicobacter
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69923559T
Other languages
English (en)
Other versions
DE69923559T2 (de
Inventor
Reuse Hilde De
Stephane Skouloubris
Valerie Cussac
Agnes Labigne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Application granted granted Critical
Publication of DE69923559D1 publication Critical patent/DE69923559D1/de
Publication of DE69923559T2 publication Critical patent/DE69923559T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/58—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving urea or urease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69923559T 1998-06-30 1999-06-29 Methoden zur inhibierung von helicobacter pylori Expired - Lifetime DE69923559T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US107383 1998-06-30
US09/107,383 US6190667B1 (en) 1998-06-30 1998-06-30 Methods of inhibiting Helicobacter pylori
PCT/EP1999/004490 WO2000000634A2 (en) 1998-06-30 1999-06-29 METHODS OF INHIBITING $i(HELICOBACTER PYLORI)

Publications (2)

Publication Number Publication Date
DE69923559D1 true DE69923559D1 (de) 2005-03-10
DE69923559T2 DE69923559T2 (de) 2006-02-16

Family

ID=22316366

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69923559T Expired - Lifetime DE69923559T2 (de) 1998-06-30 1999-06-29 Methoden zur inhibierung von helicobacter pylori

Country Status (9)

Country Link
US (5) US6190667B1 (de)
EP (1) EP1092040B1 (de)
JP (1) JP4445128B2 (de)
AT (1) ATE288498T1 (de)
AU (1) AU4779599A (de)
DE (1) DE69923559T2 (de)
ES (1) ES2237119T3 (de)
PT (1) PT1092040E (de)
WO (1) WO2000000634A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190667B1 (en) * 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
US5942409A (en) * 1998-07-31 1999-08-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for identification of substances modulating ureI dependent mechanisms of Helicobacter pylori metabolism
US20030113742A1 (en) * 2001-04-20 2003-06-19 University Of Iowa Research Foundation Methods and compositions for the modulation of biofilm formation
US20070092502A1 (en) * 2005-09-01 2007-04-26 Allergan, Inc. Method of Treating Glaucoma
EP1954548B1 (de) 2005-11-21 2010-04-28 Faroex Ltd. Verbundkarosserie für ein fahrzeug
CA2599560C (en) 2006-09-01 2011-04-12 Faroex Ltd. Structural shear plate for a vehicle
ES2545209T3 (es) 2008-04-22 2015-09-09 Corporación Alimentaria Peñasanta (Capsa) Método de obtención de una nueva cepa de Bifidobacterium bifidum con actividad frente a la infección por Helicobacter pylori
CN111471780A (zh) * 2020-03-16 2020-07-31 上海力拜生物科技有限公司 幽门螺杆菌唾液检测生物标志物及其应用
CN117050169B (zh) * 2023-08-14 2024-04-26 苏州东抗生物科技有限公司 一种针对UreA蛋白的单克隆抗体及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH25H (en) 1985-06-17 1986-02-04 Tennessee Valley Authority Thiophosphoryl triamide as a urease inhibitor
FR2637612B1 (fr) 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
GB8928625D0 (en) 1989-12-19 1990-02-21 3I Res Expl Ltd H.pylori dna probes
JPH04364160A (ja) * 1990-08-03 1992-12-16 Terumo Corp チオウレア誘導体およびこれを含有する抗菌剤および抗潰瘍剤
JPH0559038A (ja) * 1991-09-06 1993-03-09 Terumo Corp チオウレア誘導体及びこれを含有する医薬製剤
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US5409903A (en) * 1992-02-18 1995-04-25 Urecap Corporation Method and compositions for the treatment of H. pylori and dermatitis
US5472695A (en) * 1992-06-25 1995-12-05 Technion Research And Development Foundation Ltd. Therapeutic application of a thyme extract and in - vitro methods for inhibiting the growth and urease activity of helicobacter pylori
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
WO1995014093A1 (en) * 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
US5441875A (en) 1993-07-23 1995-08-15 Brigham And Women's Hospital Urea transporter polypeptide
US5560912A (en) * 1994-06-27 1996-10-01 Technion Research & Development Foundation Ltd. Method for inhibiting growth of helicobacter pylori
ATE433325T1 (de) 1995-04-28 2009-06-15 Merieux Oravax Snc Multimerer, rekombinanter urease impfstoff
DE69636320T2 (de) 1995-06-02 2007-07-26 Eisai R&D Management Co., Ltd. Helicobacter Polypeptide, deren Herstellung und Verwendung
WO1996040893A1 (en) 1995-06-07 1996-12-19 Astra Aktiebolag Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
US6087358A (en) * 1995-06-26 2000-07-11 Pathogenesis Corporation Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof
FR2736360B1 (fr) * 1995-07-04 1997-09-05 Pasteur Institut Clonage et caracterisation du gene fiba de h.pylori, production de souches aflagellees
TW290498B (en) * 1995-07-19 1996-11-11 Andover Coated Products Inc Elastic bandage
SE506529C2 (sv) * 1996-01-23 1997-12-22 Semper Ab Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
US5900410A (en) * 1996-08-27 1999-05-04 Hartmann; John F. Monotherapy of peptic ulcers and gastritis
AU5119998A (en) * 1996-10-17 1998-05-15 Institut National De La Sante Et De La Recherche Medicale A (helicobacter) antigen (gamma-glutamyltransferase) and sequences encoding the same
CA2278924A1 (en) * 1997-01-24 1998-07-30 Avi Biopharma, Inc. Method and conjugate for treating h. pylori infection
US5876946A (en) * 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
US5985631A (en) * 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US6190667B1 (en) * 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
US5942409A (en) * 1998-07-31 1999-08-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for identification of substances modulating ureI dependent mechanisms of Helicobacter pylori metabolism
EP1119454B1 (de) * 1998-10-02 2003-01-22 3M Innovative Properties Company Elastische verbundwerkstoffe
US20040142343A1 (en) * 2002-08-16 2004-07-22 Yung-Fu Chang Helicobacter bizzozeronii urease genes and their uses in diagnostic and treatment methods

Also Published As

Publication number Publication date
ATE288498T1 (de) 2005-02-15
EP1092040B1 (de) 2005-02-02
JP2002519039A (ja) 2002-07-02
AU4779599A (en) 2000-01-17
US6762051B2 (en) 2004-07-13
US20020102269A1 (en) 2002-08-01
DE69923559T2 (de) 2006-02-16
US7517666B2 (en) 2009-04-14
US6416968B1 (en) 2002-07-09
US20050176077A1 (en) 2005-08-11
ES2237119T3 (es) 2005-07-16
WO2000000634A2 (en) 2000-01-06
PT1092040E (pt) 2005-06-30
JP4445128B2 (ja) 2010-04-07
EP1092040A2 (de) 2001-04-18
US20040115772A1 (en) 2004-06-17
US6190667B1 (en) 2001-02-20
WO2000000634A3 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
ATE413386T1 (de) Ppar-gamma modulatoren
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE59902314D1 (de) Oligomerisiertes Organopolysiloxan-Cokondensat, dessen Herstellung und dessen Verwendung zur Behandlung von Oberflächen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
WO2003103581A3 (en) COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION
DE60122368D1 (de) Verwendung von Gaboxadol zur Behandlung von premenstruelle Störung, postnatal Depression oder postmenopausal-bedingte-dysphorische Störung
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
EA200200001A1 (ru) Способ повышения содержания флавоноидов и фенольных компонентов в растениях
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
DE69923559D1 (de) Methoden zur inhibierung von helicobacter pylori
ATE233483T1 (de) Wässrige lösung zum konservieren von gewebe und organen
EP1254260A4 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE345354T1 (de) Methode zur identifizierung von helicobacter antigenen
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
BR9915442A (pt) Método para a cobertura de um produto de alimento com colágeno
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
NZ514691A (en) Method to type prion proteins
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
WO2003028537A3 (en) Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
WO2003007800A8 (en) Methods for diagnosing and treating diseases and conditions of the digestive system and cancer
TW200635950A (en) Specific binding agents of human angiopoietin-2

Legal Events

Date Code Title Description
8364 No opposition during term of opposition